Skip to main content

Table 3 Associations between CYP17 genotype and breast cancer according to menopausal status

From: CYP17, GSTP1, PON1 and GLO1gene polymorphisms as risk factors for breast cancer: an Italian case-control study

  A1A1 A1A2 A2A2 A1A2 and A2A2
All     
Cases, n (%) 229 (41.9) 258 (47.1) 60 (11.0) 318 (58.1)
Controls, n (%) 227 (41.7) 249 (45.8) 68 (12.5) 317 (58.3)
OR (95% CI)a 1.0 0.95 (0.72–1.24) 0.77 (0.51–1.20)b 0.90 (0.70–1.18)
Menopausal status at diagnosis     
   Premenopausal     
Cases, n (%) 88 (47.1) 81 (43.3) 18 (9.6) 99 (52.9)
Controls, n (%) 100 (43.5) 99 (43.0) 31 (13.5) 130 (56.5)
OR (95% CI)a 1.0 0.88 (0.56–1.36) 0.66 (0.33–1.29)b 0.83 (0.55–1.25)
   Postmenopausal     
Cases, n (%) 141 (39.2) 177 (49.2) 42 (11.6) 219 (60.8)
Controls, n (%) 127 (40.4) 150 (47.8) 37(11.8) 187 (59.5)
OR (95% CI)a 1.0 0.98 (0.68–1.41) 0.94 (0.53–1.68)b 0.97 (0.69–1.38)
  1. aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen. bP for trend: all, 0.221; premenopausal, 0.389; postmenopausal, 0.954.